Please assess the completion status of the following clinical trial:

Trial Title: Follow-up to Welcome Study C87042 [NCT00308581] Examining Certolizumab Pegol (CDP870) in Subjects With Crohn's Disease

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients having completed study C87042 \[NCT00308581\] (previously treated with infliximab)~Exclusion Criteria:~* Subject withdraw from C87042 \[NCT00308581\] study~* Subject who received treatment other than certolizumab pegol and other than medications permitted in C87042 \[NCT00308581\] study~* Subjects from countries where certolizumab pegol is authorized in Crohn's disease treatment~* Female patients of childbearing age who are NOT practicing (in the Investigator's opinion) effective birth control. All female patients must test negative on a serum pregnancy test before study entry and negative on urine testing immediately before every certolizumab pegol administration

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Certolizumab pegol 400 mg (Type: EXPERIMENTAL): 400 mg subcutaneous injection of certolizumab pegol every 2 (Q2W) or 4 (Q4W) weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).